Protocol No
GSK-3377794-208467-SARCOMA
Principal Investigator
John Charlson
Phase
I/II
Summary
People with synovial sarcoma will be given a study drug GSK3377794. The purpose of this study is to help answer the following questions:
-Can GSK3377794 help participants with synovial sarcoma?
-How safe is GSK3377794 and what side effects may be related to taking it?
-Does your tumor affect how GSK3377794 works?
Description
Study of Genetically Engineered T Cells in NY-ESO-1 +/or LAGE-1a + Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category
ClinicalTrials.gov